Biopharma Viral Vector Production
Biopharma Quality Analysis
- T7 High Yield RNA Synthesis Kit（10623ES）
- Cap1-GAG(3'OMe) m7(3'OMeG)(5')ppp(5')(2'OMeA)pG (100 mM)（10677ES）
- mRNA Vaccinia Capping Enzyme GMP-grade（10614ES）
- mRNA Cap 2´-O-Methyltransferase GMP-grade (50 U/μl)（10612ES）
- Recombinant Deoxyribonuclease I (DNase I，RNase-free) GMP-grade（10611ES）
- 10× Transcription Buffer 2 GMP-grade（10670ES）
- Pseudo UTP sodium solution GMP-grade (100 mM)（10650ES）
- RNase H (60 U/μL)（14522ES）
- ATP Solution GMP-grade (100 mM)（10129ES）
mRNA technology is one of the greatest biotech breakthroughs in 21st century. mRNAs primarily encodes proteins and can be used in the development of prophylactic and therapeutic vaccines or drugs against a variety of diseases including infections and cancers. Yeasen is dedicated to providing our customers with high-quality products and professional support not only to accelerate their R&D projects from initial research to clinical trials, but also guarantee mRNA vaccine production with high efficiency. At present, products supplied by Yeasen include restriction endonucleases, T7 RNA polymerase, inorganic pyrophosphatase, RNase inhibitor, vaccinia capping enzyme, 2´-O-Methyltransferase, DNase I, S-adenosylmethionine, cap analogs, natural and modified nucleoside triphosphates.
